Related Experiment Video

Updated: Mar 8, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

794

A Vulnerable Age for the Introduction of Solid Foods in Pediatric Acute Lymphoblastic Leukemia

Jeremy M Schraw1, Michael E Scheurer2, Michele R Forman1

  • 1a Department of Nutritional Sciences , University of Texas at Austin , Austin , Texas , USA.

Nutrition and Cancer
|January 18, 2017
PubMed

Insights

Introducing solid foods later in infancy, after 6 months, was linked to a higher risk of childhood acute lymphoblastic leukemia (ALL). Breastfeeding and timely introduction of solids are recommended.

Area of Science:

  • Pediatric Oncology
  • Epidemiology
  • Environmental Health

Background:

  • Limited research exists on infant feeding practices and pediatric acute lymphoblastic leukemia (ALL).
  • Understanding risk factors for ALL is crucial for early detection and prevention.

Purpose of the Study:

  • To investigate the association between the age of solid food introduction and the risk of pediatric ALL.
  • To explore the role of infant formula feeding in relation to pediatric ALL.

Main Methods:

  • A case-control study involving 171 pediatric ALL cases and 342 matched controls.
  • Data collected on infant feeding, including age at introduction of solids and formula use.
  • Multivariable logistic regression analysis to calculate odds ratios (OR) for ALL risk.

Main Results:

  • Later introduction of solids (7-9 months and ≥10 months) was associated with significantly increased odds of ALL (OR=4.08 and OR=6.03, respectively).
  • Each additional month of infant formula feeding correlated with a 16% increased odds of ALL (OR=1.16).

Conclusions:

  • A later introduction to solid foods presents a potential risk factor for pediatric ALL.
  • Adherence to American Academy of Pediatrics guidelines for introducing solids is advised.
Abstract

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.7K
Modeling Chemotherapy Resistant Leukemia In Vitro08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

9.6K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
343
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
586
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
405
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
304
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
628
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
2.1K